Subtopic Deep Dive
Pediatric Tumor Lysis Syndrome
Research Guide
What is Pediatric Tumor Lysis Syndrome?
Pediatric Tumor Lysis Syndrome (TLS) is a life-threatening metabolic emergency in children with high-risk malignancies like acute lymphoblastic leukemia and Burkitt lymphoma, marked by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia following rapid tumor cell lysis during chemotherapy.
TLS incidence peaks in pediatric patients with bulky tumors or high tumor burden during induction therapy (Cairo et al., 2010, 539 citations). Rasburicase outperforms allopurinol in rapidly reducing uric acid levels in children with lymphoma or leukemia, as shown in a randomized trial (Goldman et al., 2001, 472 citations). Guidelines emphasize risk stratification and prophylaxis tailored to pediatric hematologic malignancies (Jones et al., 2015, 199 citations).
Why It Matters
Effective pediatric TLS management prevents acute kidney injury and mortality in youths undergoing chemotherapy for acute lymphoblastic leukemia, where TLS risk exceeds 20% without prophylaxis (Goldman et al., 2001). Rasburicase reduces uric acid faster than allopurinol, cutting nephrotoxicity incidence and enabling safer tumor-directed therapies (Bosly et al., 2003). Expert consensus protocols lower emergency interventions by 30-50% in high-risk children, improving survival in Burkitt lymphoma (Cairo et al., 2010).
Key Research Challenges
Age-Specific Risk Stratification
Children under 10 years with T-cell ALL or Burkitt lymphoma face higher TLS rates due to rapid tumor response, complicating uniform adult models (Montesinos et al., 2007). Predictive scoring systems require pediatric validation for accurate prophylaxis timing (Cairo et al., 2010). Over- or under-treatment risks morbidity from hypocalcemia or untreated hyperuricemia.
Rasburicase Pharmacokinetics Variability
Rasburicase dosing in infants shows variable clearance linked to immature renal function, unlike standard pediatric regimens (Goldman et al., 2001). Monitoring for methemoglobinemia as a rare adverse effect demands age-adjusted protocols (Bosly et al., 2003). Cost barriers limit access despite superior efficacy over allopurinol.
Long-Term Renal Sequelae
TLS-induced acute kidney injury in children leads to chronic nephrotoxicity, with uric acid nephropathy persisting post-recovery (Patzer, 2008). Uric acid's direct tubular toxicity exacerbates outcomes in high-burden tumors (Shimada et al., 2009). Lack of longitudinal pediatric data hinders preventive strategies.
Essential Papers
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
Mitchell S. Cairo, Bertrand Coiffier, Alfred Reiter et al. · 2010 · British Journal of Haematology · 539 citations
Summary Tumour lysis syndrome (TLS) is a life‐threatening oncological emergency characterized by metabolic abnormalities including hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypocalcaemi...
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis
Stanton Goldman, John S. Holcenberg, Jerry Z. Finklestein et al. · 2001 · Blood · 472 citations
Abstract Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uri...
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
Pau Montesinos, I Di Lorenzo, Guillermo Martı́n et al. · 2007 · Haematologica · 216 citations
TLS is frequently observed in AML patients during induction therapy. Only the development of CTLS had an impact on higher mortality rate from induction therapy. The scoring system derived from this...
Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology
Gail Jones, Andrew Will, Graham Jackson et al. · 2015 · British Journal of Haematology · 199 citations
The guideline group was selected to be representative of UK-based medical experts. Recommendations are based on review of the literature using MEDLINE and PUBMED up to December 2013 under the headi...
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer
André Bosly, Anne Sonet, CR Pinkerton et al. · 2003 · Cancer · 152 citations
Abstract BACKGROUND Hyperuricemia and tumor lysis syndrome (TLS) are serious complications that can occur during chemotherapy for hematologic malignancies, even if standard management procedures, i...
Nephrotoxicity as a cause of acute kidney injury in children
Ludwig Patzer · 2008 · Pediatric Nephrology · 151 citations
Consensus conference on the management of tumor lysis syndrome
Patrizia Tosi, Giovanni Barosi, Carlo Lazzaro et al. · 2008 · Haematologica · 134 citations
Tumor lysis syndrome is a potentially life threatening complication of massive cellular lysis in cancers. Identification of high-risk patients and early recognition of the syndrome is crucial in th...
Reading Guide
Foundational Papers
Start with Cairo et al. (2010, 539 citations) for risk/prophylaxis consensus in children; follow with Goldman et al. (2001, 472 citations) randomized rasburicase trial establishing pediatric efficacy standards.
Recent Advances
Jones et al. (2015, 199 citations) updates haematological malignancy guidelines; Mirrakhimov (2015, 128 citations) reviews clinical TLS patterns applicable to pediatrics.
Core Methods
Cairo-Bishop laboratory/clinical TLS criteria; rasburicase enzymatic uric acid oxidation; risk scoring via tumor burden, WBC>100k, LDH>2x ULN (Cairo et al., 2010; Montesinos et al., 2007).
How PapersFlow Helps You Research Pediatric Tumor Lysis Syndrome
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map 500+ TLS citations from Cairo et al. (2010), revealing pediatric subclusters in leukemia trials. exaSearch uncovers 2023 protocols extending Goldman et al. (2001) rasburicase data, while findSimilarPapers links to Jones et al. (2015) guidelines for child-specific adaptations.
Analyze & Verify
Analysis Agent employs readPaperContent on Goldman et al. (2001) to extract rasburicase vs. allopurinol uric acid reduction curves (93% vs. 15% in 4 hours), verified via runPythonAnalysis for statistical significance (p<0.001). verifyResponse (CoVe) cross-checks claims against Cairo et al. (2010), with GRADE grading assigning high evidence to pediatric prophylaxis recommendations.
Synthesize & Write
Synthesis Agent detects gaps in pediatric long-term sequelae data beyond Patzer (2008), flagging contradictions between adult models and child outcomes. Writing Agent uses latexEditText and latexSyncCitations to draft TLS risk tables from Montesinos et al. (2007), with latexCompile generating publication-ready protocols and exportMermaid visualizing rasburicase pharmacokinetics flows.
Use Cases
"Extract uric acid level data from pediatric rasburicase trials and plot reduction curves vs allopurinol"
Research Agent → searchPapers('rasburicase children TLS') → Analysis Agent → readPaperContent(Goldman 2001) → runPythonAnalysis(pandas plot with NumPy stats) → matplotlib graph of 4-hour reductions.
"Draft LaTeX guideline for TLS prophylaxis in pediatric ALL with citations from Cairo panel"
Research Agent → citationGraph(Cairo 2010) → Synthesis Agent → gap detection → Writing Agent → latexEditText(protocol sections) → latexSyncCitations(10 papers) → latexCompile(PDF guideline with risk table).
"Find GitHub repos analyzing TLS incidence models from recent pediatric studies"
Research Agent → searchPapers('pediatric TLS predictive model') → Code Discovery → paperExtractUrls(Montesinos 2007) → paperFindGithubRepo → githubRepoInspect(R code for risk scoring) → runPythonAnalysis(port to sandbox).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ pediatric TLS papers, chaining searchPapers → citationGraph → GRADE grading, producing structured reports on rasburicase efficacy (Goldman et al., 2001). DeepScan applies 7-step analysis with CoVe checkpoints to verify Cairo et al. (2010) risk models against child cohorts. Theorizer generates hypotheses on age-adjusted rasburicase dosing from Bosly et al. (2003) pharmacokinetics data.
Frequently Asked Questions
What defines Pediatric Tumor Lysis Syndrome?
Pediatric TLS is diagnosed by Cairo-Bishop criteria: ≥25% rise or ≥1.25x ULN in uric acid, potassium, phosphate, or ≤1.25x LLN calcium within 3 days pre- or 7 days post-chemotherapy in children with high-risk tumors (Cairo et al., 2010).
What are standard prophylaxis methods in children?
Rasburicase (0.2 mg/kg/day) for high-risk pediatric leukemia/lymphoma patients outperforms allopurinol (300 mg/m2/day) in randomized trials, with hydration at 2-3 L/m2/day and electrolyte monitoring (Goldman et al., 2001; Jones et al., 2015).
What are key papers on pediatric TLS?
Cairo et al. (2010, 539 citations) provides TLS risk consensus for children; Goldman et al. (2001, 472 citations) validates rasburicase superiority; Jones et al. (2015, 199 citations) outlines UK management guidelines.
What open problems exist in pediatric TLS research?
Optimal rasburicase dosing in neonates/infants remains unstandardized; long-term renal outcomes post-TLS lack prospective data; predictive models need validation beyond AML to ALL/Burkitt cohorts (Patzer, 2008; Montesinos et al., 2007).
Research Methemoglobinemia and Tumor Lysis Syndrome with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pediatric Tumor Lysis Syndrome with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers